KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $467.4 million.

  • Vertex Pharmaceuticals' Other Operating Expenses rose 1458.69% to $467.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 6404.36%. This contributed to the annual value of $6.2 billion for FY2024, which is 25439.95% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Other Operating Expenses of $467.4 million as of Q3 2025, which was up 1458.69% from $410.6 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Operating Expenses peaked at $4.8 billion during Q2 2024, and registered a low of $188.4 million during Q1 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Other Operating Expenses averaged around $667.8 million, with its median value being $407.9 million (2024).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Other Operating Expenses surged by 105209.08% in 2024, and later tumbled by 9148.4% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Operating Expenses (Quarter) stood at $371.9 million in 2021, then fell by 17.26% to $307.7 million in 2022, then grew by 9.03% to $335.5 million in 2023, then soared by 51.92% to $509.7 million in 2024, then decreased by 8.3% to $467.4 million in 2025.
  • Its last three reported values are $467.4 million in Q3 2025, $410.6 million for Q2 2025, and $764.0 million during Q1 2025.